Item 16. Form 10-K Summary
5K characters. Original on sec.gov · Markdown
Item 16. Form 10-K Summary
None.
SIGNATURES
Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| CADENCE DESIGN SYSTEMS, INC. | |||||
| /s/ Anirudh Devgan | |||||
| Anirudh Devgan | |||||
| President and Chief Executive Officer | |||||
| Dated: | February 18, 2026 |
Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated.
| /s/ Anirudh Devgan | DATE: | February 18, 2026 | ||||||
| Anirudh Devgan | ||||||||
| President and Chief Executive Officer | ||||||||
| (Principal Executive Officer) | ||||||||
| /s/ John M. Wall | DATE: | February 18, 2026 | ||||||
| John M. Wall | ||||||||
| Senior Vice President and Chief Financial Officer | ||||||||
| (Principal Financial and Accounting Officer) |
POWER OF ATTORNEY
KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints Anirudh Devgan, John M. Wall and Marc Taxay, and each of them, as his or her true and lawful attorneys-in-fact and agents, with full power of substitution and resubstitution, for him or her and in his or her name, place and stead, in any and all capacities, to sign any and all amendments (including post-effective amendments) to this Report on Form 10-K, and to file the same, with all exhibits thereto, and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing requisite and necessary to be done in connection therewith, as fully to all intents and purposes as he or she might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact and agents, or any of them, or their, his or her substitute or substitutes, may lawfully do or cause to be done by virtue hereof.
Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated:
| /s/ | ML Krakauer | February 18, 2026 | ||||||||||||
| ML, Chair | ||||||||||||||
| /s/ | Mark W. Adams | February 18, 2026 | ||||||||||||
| Mark W. Adams, Director | ||||||||||||||
| /s/ | Ita Brennan | February 18, 2026 | ||||||||||||
| Ita Brennan, Director | ||||||||||||||
| /s/ | Lewis Chew | February 18, 2026 | ||||||||||||
| Lewis Chew, Director | ||||||||||||||
| /s/ | Anirudh Devgan | February 18, 2026 | ||||||||||||
| Anirudh Devgan, Director | ||||||||||||||
| /s/ | Moshe Gavrielov | February 18, 2026 | ||||||||||||
| Moshe Gavrielov, Director | ||||||||||||||
| /s/ | Julia Liuson | February 18, 2026 | ||||||||||||
| Julia Liuson, Director | ||||||||||||||
| /s/ | Dr. James D. Plummer | February 18, 2026 | ||||||||||||
| Dr. James D. Plummer, Director | ||||||||||||||
| /s/ | Dr. Alberto Sangiovanni-Vincentelli | February 18, 2026 | ||||||||||||
| Dr. Alberto Sangiovanni-Vincentelli, Director | ||||||||||||||
| /s/ | Young K. Sohn | February 18, 2026 | ||||||||||||
| Young K. Sohn, Director | ||||||||||||||
| /s/ | Dr. Luc Van den hove | February 18, 2026 | ||||||||||||
| Dr. Luc Van den hove, Director | ||||||||||||||
Previous: Item 15. Exhibits and Financial Statement Schedules